166 related articles for article (PubMed ID: 11959221)
1. The limitations of calcineurin and mTOR inhibitors: new directions for immunosuppressive strategies.
Kahan BD
Transplant Proc; 2002 Feb; 34(1):130-3. PubMed ID: 11959221
[No Abstract] [Full Text] [Related]
2. Sirolimus to replace calcineurin inhibitors? Too early yet.
Cravedi P; Ruggenenti P; Remuzzi G
Lancet; 2009 Apr; 373(9671):1235-6. PubMed ID: 19362662
[No Abstract] [Full Text] [Related]
3. Reduced exposure to calcineurin inhibitors in renal transplantation.
Guba M; Jauch KW
N Engl J Med; 2008 Jun; 358(23):2518; author reply 2519-20. PubMed ID: 18525054
[No Abstract] [Full Text] [Related]
4. mTOR Inhibition and Clinical Transplantation: Kidney.
Flechner SM
Transplantation; 2018 Feb; 102(2S Suppl 1):S17-S18. PubMed ID: 28230636
[No Abstract] [Full Text] [Related]
5. The pros and the cons of mTOR inhibitors in kidney transplantation.
Ponticelli C
Expert Rev Clin Immunol; 2014 Feb; 10(2):295-305. PubMed ID: 24377908
[TBL] [Abstract][Full Text] [Related]
6. mTOR Inhibition and Clinical Transplantation: Heart.
Zuckermann A; Osorio-Jaramillo E; Aliabadi-Zuckermann AZ
Transplantation; 2018 Feb; 102(2S Suppl 1):S27-S29. PubMed ID: 29369971
[TBL] [Abstract][Full Text] [Related]
7. The evolving role of tor inhibitors for individualizing posttransplant immunosuppression.
Lorber MI; Basadonna GP; Friedman AL; Lorber KM; Bia MJ; Formica R; Smith JD
Transplant Proc; 2001; 33(7-8):3075-7. PubMed ID: 11750322
[No Abstract] [Full Text] [Related]
8. Transplantation: time to rethink immunosuppression by mTOR inhibitors?
Säemann MD; Remuzzi G
Nat Rev Nephrol; 2009 Nov; 5(11):611-2. PubMed ID: 19855420
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation.
Nguyen LS; Vautier M; Allenbach Y; Zahr N; Benveniste O; Funck-Brentano C; Salem JE
Drug Saf; 2019 Jul; 42(7):813-825. PubMed ID: 30868436
[TBL] [Abstract][Full Text] [Related]
10. The Long Journey of mTOR Inhibitors and the Long Path That Is Still Ahead.
Tedesco Silva H
Transplantation; 2018 Feb; 102(2S Suppl 1):S1-S2. PubMed ID: 29369969
[No Abstract] [Full Text] [Related]
11. Current trends in immunosuppression.
González Posada JM
Nefrologia; 2006; 26 Suppl 2():3-8. PubMed ID: 17937629
[No Abstract] [Full Text] [Related]
12. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs.
Lindenfeld J; Miller GG; Shakar SF; Zolty R; Lowes BD; Wolfel EE; Mestroni L; Page RL; Kobashigawa J
Circulation; 2004 Dec; 110(25):3858-65. PubMed ID: 15611389
[No Abstract] [Full Text] [Related]
13. Recent Advances in Mammalian Target of Rapamycin Inhibitor Use in Heart and Lung Transplantation.
Fine NM; Kushwaha SS
Transplantation; 2016 Dec; 100(12):2558-2568. PubMed ID: 27495747
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
[TBL] [Abstract][Full Text] [Related]
15. Tailoring immunosuppressive therapy.
Kuypers DR; Vanrenterghem YC
Nephrol Dial Transplant; 2002 Dec; 17(12):2051-4. PubMed ID: 12454210
[No Abstract] [Full Text] [Related]
16. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
[TBL] [Abstract][Full Text] [Related]
17. High Incidence of Ovarian Cysts in Women Receiving mTOR Inhibitors After Renal Transplantation.
Bachmann F; Glander P; Budde K; Bachmann C
J Womens Health (Larchmt); 2018 Mar; 27(3):394-398. PubMed ID: 29087803
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus and cyclosporin for renal transplantation.
Halloran PF
Lancet; 2000 Jul; 356(9225):179-80. PubMed ID: 10963190
[No Abstract] [Full Text] [Related]
19. Immunosuppressive minimization with mTOR inhibitors and belatacept.
Diekmann F
Transpl Int; 2015 Aug; 28(8):921-7. PubMed ID: 25959589
[TBL] [Abstract][Full Text] [Related]
20. Safety of mTOR inhibitors in adult solid organ transplantation.
Ventura-Aguiar P; Campistol JM; Diekmann F
Expert Opin Drug Saf; 2016; 15(3):303-19. PubMed ID: 26667069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
